Keyphrases
Parkinson's Disease
100%
Deep Brain Stimulation
21%
Multiple System Atrophy
19%
Meta-analysis
19%
Patients with Parkinson's Disease
18%
Parkinson Patients
13%
Hospitalized Patients
12%
Confidence Interval
11%
Parkinsonism
11%
Dyskinesia
11%
Movement Disorders
10%
Clinical Features
10%
Ethnic Groups
8%
Racial Groups
8%
Motor Fluctuations
8%
Globus Pallidus Internus
8%
Vertical Supranuclear Gaze Palsy
8%
Hispanic
8%
PDQ-39
8%
Clinical Phenotype
7%
Non-motor Symptoms
7%
Progressive Supranuclear Palsy
7%
Dystonia
7%
Clinical Outcomes
7%
Unified Parkinson's Disease Rating Scale (UPDRS)
7%
Deep Brain Stimulation Surgery
6%
Clinical Trials
6%
White Patients
6%
Novel Therapies
6%
Minority Enrollments
6%
Economic Outcomes
6%
MPPD Model
6%
Ethnoracial Differences
6%
Periodic Limb Movements
6%
Dysphagia
6%
Neuromodulation Therapy
6%
Pallido-nigro-luysian Atrophy
6%
Tau Proteinopathy
6%
Cannabis Oil
6%
Wearing-off
6%
Caudal Zona Incerta
6%
Ventral Intermediate nucleus
6%
Epidemiology
6%
Arm Swing
6%
Orofacial Dyskinesia
6%
Palliative Care Use
6%
GNB1
6%
Center of Excellence
6%
Fat Mass
6%
Gender Disparity
6%
Medicine and Dentistry
Parkinson's Disease
58%
Deep Brain Stimulation
22%
Stereotypic Movement Disorder
13%
Gaze Paralysis
12%
Shy-Drager Syndrome
12%
Globus pallidus
11%
Alzheimer's Disease
9%
Progressive Supranuclear Palsy
9%
Quality of Life
9%
Parkinsonism
8%
Racial Group
8%
Ethnic Group
8%
Dystonia
8%
Tau
6%
Nephrology
6%
Orofacial Dyskinesia
6%
Leishmaniasis
6%
Myoclonus
6%
Plummer-Vinson Syndrome
6%
Race Difference
6%
Mixed Infection
6%
Neglected Tropical Diseases
6%
Cryptococcosis
6%
Symptomatic Treatment
6%
Zona Incerta
6%
Essential Tremor
6%
Treatment of Parkinson's Disease
6%
Anti N Methyl D Aspartate Receptor Encephalitis
6%
Spasmodic dysphonia
6%
Periodontal Disease
6%
Amyloid Protein
6%
Cognition
6%
Meta-Analysis
6%
Phosphoglycerate Kinase
5%
Levodopa
5%
Speech Production
5%